



Atty. Dkt. No. 038602-1153

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Malcolm Wilson MOON et al.

Title:

MANNICH BASE PRODRUGS OF 3-(PYRROL-2-YL-METHYLIDENE)-2-

INDOLINONE DERIVATIVES

Appl. No.:

09/863,804

Filing Date:

05/24/2001

Examiner:

Rebecca Anderson

Art Unit:

1626

AMENDMENT AND REPLY UNDER 37 CFR 1.116

Mail Stop NON-FEE AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

This communication is responsive to the Final Office Action dated May 29, 2003, concerning the above-referenced patent application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 5 of this document.

Please amend the application as follows:

enter to

This listing of claims will replace all prior versions, and listings, of claims in the application: Listing of Claims:

Claim 1. (Currently amended) A compound of the Formula (I):

wherein:

R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and -NR¹¹R¹² where R¹¹ and R¹² are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, and trifluoromethanesulfonyl, or R¹¹ and R¹², together with the nitrogen atom to which they are attached, combine to form a five- or six-member heteroalicyclic ring provided that at least two of R³, R⁴, R⁵ and R⁶ are hydrogen; or

R³ and R⁴, R⁴ and R⁵, or R⁵ and R⁶ may combine to form a six-membered aryl ring, a methylenedioxy group or an ethylenedioxy group;

R⁷ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy,

alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, carbonyl, C-carboxy, O-carboxy, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and -NR¹¹R¹², wherein R¹¹ and R¹² are as defined above:

R1' is hydrogen or alkyl; and

R^{3'} and R^{4'} form an unsubstituted heteroalicyclic ring provided that the heteroalicyclic ring is not piperidin 1-yl or morpholin 4-yl pyrrolidin-1-yl ring; or a pharmaceutically acceptable salt thereof.

Claims 2 - 5 (Cancelled).

Claim 6. (Original) The compound of any one of Claims 2, 3, 4, or 5 wherein R^1 and R^7 are hydrogen.

Claim 7. (Currently amended) The compound of Claim 1, wherein R^3 , R^4 , R^5 , R^6 , R^7 , and R^9 are hydrogen, and R^8 and R^{10} are unsubstituted lower alkyl; and $R^{3^{10}}$ and $R^{4^{10}}$ combine to form a heteroalicyclic ring.

Claim 8. (Original) The compound of Claim 7, wherein R^8 and R^{10} are methyl and $R^{1'}$ is hydrogen.

Claim 9 (Cancelled).

Claim 10. (Original) The compound of Claim 1, wherein R^3 , R^4 , R^5 , R^6 , and R^7 are hydrogen and R^8 and R^{10} are unsubstituted lower alkyl.

Claim 11. (Original) The compound of Claim 10, wherein R^9 is C-amido or lower alkyl substituted with carboxy and R^1 and R^7 are hydrogen.

Claim 12. (Currently amended) The compound of Claim 11, wherein R⁸ and R¹⁰ are methyl-and R²² and R²³ combine to form a heteroalicyclic ring.

Claim 13. (Cancelled).

Claims 14 – 19 (Cancelled).

Claim 20. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 1.

Claim 21 (cancelled).

Claim 22. (Original) The pharmaceutical composition of Claim 20, wherein said composition is administered parenterally.

Claims 23-36 (cancelled).